Shares of Merus NV (MRUS) are soaring 5.17% in Thursday's intraday trading session, outperforming the broader market. The significant uptick in the stock price comes as Wells Fargo reaffirms its confidence in the biopharmaceutical company.

According to a recent report, Wells Fargo has maintained its Overweight rating on Merus NV. This positive stance from a major financial institution appears to be driving investor optimism, contributing to the stock's impressive gains today. An Overweight rating typically suggests that analysts believe the stock will outperform its sector or the overall market.

While specific details of Wells Fargo's analysis were not immediately available, the maintained Overweight rating implies continued confidence in Merus NV's business model, pipeline, or growth prospects. Investors are likely interpreting this as a positive signal about the company's future performance in the competitive healthcare sector. As always, market participants are advised to conduct their own research and consider multiple factors when making investment decisions.